Eros Apothecary Recalls Honey Supplement After FDA Testing Finds Undeclared Tadalafil

Undeclared tadalafil in a dietary supplement sold through a third-party e-commerce platform has triggered a voluntary recall by Eros Apothecary of Indio, California, a case that sharpens the compliance burden on QA teams overseeing products distributed outside conventional retail channels. The FDA confirmed the finding through laboratory testing, with the recall announced on November 12, 2026.

The implicated product, Candy Power For Man Organic Honey, was sold via eBay between April 27, 2026, and July 20, 2026. Packaged in yellow and orange labeling with 60 individually wrapped candies per unit, the product carries Batch 241020, a manufacturing date of January 2024, and an expiration date of December 2029 (UPC: 5285002251390). None of the labeling declared tadalafil as an ingredient.

Tadalafil is the active pharmaceutical ingredient in Cialis, an FDA-approved prescription treatment for erectile dysfunction restricted to use under licensed clinical supervision. Its presence in an unlabeled supplement creates a direct patient safety risk: tadalafil is contraindicated with nitrate-containing medications such as nitroglycerin, and co-administration can produce a clinically significant drop in blood pressure. Populations most exposed to that interaction, patients managing diabetes, hypertension, hypercholesterolemia, or cardiovascular disease, are also among the most likely to be taking nitrate therapy concurrently.

For QA directors and regulatory affairs leads, the enforcement pattern here is familiar but unresolved. Dietary supplements marketed through e-commerce marketplaces fall within 21 CFR Part 111 GMP requirements, yet third-party platform sales complicate lot traceability, post-market surveillance, and consumer notification reach. FDA's detection via laboratory testing rather than a manufacturer-initiated out-of-specification investigation points to a gap in internal quality oversight that regulators will scrutinize during any subsequent inspection.

The recall also illustrates a persistent challenge in supply chain vigilance: products containing undeclared APIs can move through unregulated distribution channels for months before enforcement action is initiated. The April-to-July sales window represents nearly three months of market exposure before FDA laboratory results prompted action.

Consumers are directed to discontinue use immediately and dispose of remaining product; adverse events should be submitted through FDA MedWatch. Eros Apothecary can be reached at [email protected] for recall-related inquiries.

FDA's continued use of laboratory surveillance as the primary detection mechanism for adulterated supplements sold via e-commerce underscores the gap between current third-party marketplace oversight and the post-market controls that ICH Q10 pharmaceutical quality systems are designed to close.

Source: U.S. Food and Drug Administration, Recalls, Market Withdrawals and Safety Alerts, November 12, 2026.